Company Overview of OpGen, Inc.
OpGen, Inc., a whole genome analysis company, engages in developing and commercializing genomic and DNA analysis systems and services worldwide. It offers Argus Optical Mapping System, a platform for automated and microbial whole genome analysis that brings comparative genomics, whole genome sequence assembly, and strain characterization into laboratory; and Argus whole genome mapping and genome builder software solution. The company also provides MapIt Optical Mapping Services as a commercial laboratory for specific microbial projects on a by-quotation basis for applications in the areas of clinical and food microbiology, epidemiology, pharmacology, manufacturing quality control, and applie...
708 Quince Orchard Road
Gaithersburg, MD 20878
Founded in 2001
Key Executives for OpGen, Inc.
Chief Executive Officer and Director
Vice President of Business Development & Operations
Senior Vice President of Commercial Operations
Compensation as of Fiscal Year 2013.
OpGen, Inc. Key Developments
OpGen, Inc. and Hitachi High-Technologies Corporation Enter into an Agreement to Develop Human Chromosome Mapping Analytical Service
Oct 16 13
OpGen, Inc. and Hitachi High-Technologies Corporation announced an agreement to develop a comprehensive human chromosome mapping analytical service for clinical research applications by a combination of OpGen's market-leading Whole Genome Mapping(TM) technology and Hitachi High-Technologies' and Hitachi group's cloud-based systems. This service will include bioinformatics tools to complete human genome sequence, and detect and analyze structural variations in human chromosomes. Under the terms of this agreement, Hitachi High-Technologies will fund development, and the companies will work together to combine the strengths of their proprietary technologies. OpGen's Whole Genome Mapping provides a unique view into structural variation in human chromosomes and offers a more accurate and complete analysis of the human genome than next generation sequencing data alone can provide. Many structural variations are associated with cancer, autism, Alzheimer's disease and many other cognitive disorders. This type of genetic information will enable development of new therapies, and eventually will empower the broader healthcare community to diagnose and guide treatment decisions based on a patient's genetic profile.
OpGen, Inc. Announces Partnership with Applied Maths to Provide Bioinformatics Analysis Software for Whole Genome Mapping
Jun 3 13
OpGen, Inc. announced the company has entered into a strategic collaboration with Applied Maths NV, to provide advanced software tools for microbial genomics and molecular strain typing. Under the agreement, Applied Maths has incorporated a Whole Genome Mapping module into the company's new BioNumerics 7 software suite, providing customers with seamless access to a new set of analytical tools for molecular typing and comparative genomics of microbial pathogens.
OpGen, Inc. Announces Partnership with University of California, Davis, to Develop High Resolution Microbial Genetic Maps in Support of the 100K Genome Project
Dec 19 12
OpGen, Inc. announced the company has entered into a scientific and technical partnership with the University of California, Davis, (UC Davis) in cooperation with the FDA supported 100K Genome Project to create high resolution microbial genetic maps. The 100K Genome Project is a collaboration that was initiated by the U.S. Food and Drug Administration (FDA), UC Davis, and Agilent Technologies to sequence the genetic code of at least 100,000 infectious organisms and accelerate the diagnosis of foodborne illnesses. UC Davis will integrate OpGen's Argus Whole Genome Mapping System into its current DNA sequencing workflow for sequence assembly and validation of the genomes. Through the integration of OpGen's Whole Genome Mapping technology, The 100K Genome Project will create a new gold standard for high-quality microbial reference genomes. These data will be used in the surveillance and management of international foodborne microbial outbreaks, and to establish a high-fidelity global reference database for microbial genomes. The 100K Genome Project will publish the genomes that are completed and validated using OpGen's Whole Genome Maps to a database, providing access to the genomic maps for public health agencies throughout the world. The FDA is advocating rigorous quality control standards for this reference database whereby genomic information should be validated by two independent methods. The Centers for Disease Control and Prevention (CDC) estimates that each year roughly one in six Americans (or 48 million people) become sick, 128,000 are hospitalized, and 3,000 die of foodborne diseases.(1) There are 31 known foodborne pathogens, including Salmonella, Listeria, and E. coli, among others.(1) Many of these pathogens are tracked by public health systems that track diseases and outbreaks.(1) Rapid identification and detection of these pathogens can lead to more effective control and management of microbial disease outbreaks.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 18, 2013